NeuroPaceNPCE -0.40%65 Days Payable is 76.37 as of Mar. 2026, which is 84% above its 10-year median of 41.45. GuruFocus rates NPCE with a GF Score™ of 65/100 and a GF Value™ of $11.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, NeuroPace ranks worse than 50.06% on this metric.
NeuroPace's average Accounts Payable for the
three
months ended in Mar. 2026 was $3.36 Mil. NeuroPace's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $4.02 Mil.
Hence, NeuroPace's Days Payable for the
three
months ended in Mar. 2026 was 76.37.
The historical rank and industry rank for NeuroPace's Days Payable or its related term are showing as below:
NPCE'
s Days Payable Range Over the Past 10 Years
Min: 31.11 Med: 41.45 Max: 67.87
Current: 67.87
During the past 7 years, NeuroPace's highest Days Payable was 67.87. The lowest was 31.11. And the median was 41.45.
NPCE's Days Payable is ranked worse than 50.06% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs NPCE: 67.87
NeuroPace's Days Payable
increased
from Mar. 2025 (61.63) to Mar. 2026 (76.37).
It may suggest that NeuroPacedelayed paying its suppliers.
NeuroPace Days Payable Related Terms
NeuroPace Days Payable Historical Data
* Premium members only.
The historical data trend for NeuroPace's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NeuroPace's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's Days Payable distribution charts can be found below:
* The bar in red indicates where NeuroPace's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
NeuroPace's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroPace (NPCE) has a Days Payable of 76.37 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NeuroPace and its competitors. This is 84% above median its historical median of 41.45. Over the past decade, NeuroPace's Days Payable has ranged from 31.11 to 67.87. According to the industry distribution chart, NeuroPace ranks #398 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 50.1%.
Is NeuroPace's Days Payable too high?
NeuroPace's current Days Payable of 76.37 is 84% above median its 10-year median of 41.45. Over the past 10 years, this metric has ranged from a low of 31.11 to a high of 67.87. The Medical Devices & Instruments industry median Days Payable is 67.87. NeuroPace's value of 76.37 is 12.5% above this industry median. Based on the distribution chart, NeuroPace ranks #398 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NeuroPace has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's Days Payable compare to TCMD and BVS?
According to the Medical Devices & Instruments industry distribution chart, NeuroPace ranks #398 out of 795 companies for Days Payable. This places NeuroPace in the lower half of its industry. The industry median Days Payable is 67.87. NeuroPace's value of 76.37 is 12.5% above this benchmark. Historically, NeuroPace's own Days Payable has ranged from 31.11 to 67.87 over the past decade. While the company's 10-year median is 41.45 vs. the industry median of 67.87, NeuroPace has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroPace's current Days Payable of 76.37 is 12.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NeuroPace and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroPace's current Days Payable is 76.37, which is 84% above median its own 10-year median of 41.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.41, compared to a current price of $16.30 — trading 42.8% above its estimated fair value. The current Days Payable is 76.37, which is 84% above median its 10-year median of 41.45 and 12.5% above the Medical Devices & Instruments industry median of 67.87. NeuroPace's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For NeuroPace (NPCE), the current Days Payable is 76.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $16.30 is trading 42.8% above its estimated GF Value™ of $11.41.
GuruFocus considers NeuroPace to be Significantly Overvalued.
Key valuation signals for NPCE:
Days Payable: 76.37 (84% above median its 10-year median of 41.45)
GF Value™: $11.41 vs. price of $16.30 (42.8% above fair value)
Industry Position: 12.5% above the Medical Devices & Instruments median (#398 of 795)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
65GF Score
Get the complete analysis for NPCE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 
